Founded at the Abramson Cancer Center at the University of Pennsylvania

Adoption of Immune Checkpoint Inhibitors and Patterns of Care at the End of Life

By Fauzia Riaz, MD, MHS; Geliang Gan, PhD; Fangyong Li, MPH; Amy J. Davidoff, PhD; Kerin B. Adelson, MD; Carolyn J. Presley, MD, MHS; Blythe J. Adamson, PhD, MPH; Pooja Shaw, MBA; Ravi B. Parikh, MD, MPP; Ronac Mamtani, MD; Cary P. Gross, MD

Adoption of Immune Checkpoint Inhibitors and Patterns of Care at the End of Life


JCO Oncology Practice | 2020

Fauzia Riaz, MD, MHS; Geliang Gan, PhD; Fangyong Li, MPH; Amy J. Davidoff, PhD; Kerin B. Adelson, MD; Carolyn J. Presley, MD, MHS; Blythe J. Adamson, PhD, MPH; Pooja Shaw, MBA; Ravi B. Parikh, MD, MPP; Ronac Mamtani, MD; Cary P. Gross, MD